Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis B vaccine immune response in OCD patients receiving high-dose paroxetine
NL-OMON38586Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2014
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Hepatitis B vaccine and paroxetine in hepatitis B (HBV) and obsessive compulsive disorder (OCD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Anti-HBs antibody titers, HBsAg-specific cellular T-cell response and 4 more. Started Nov 2014; status: active, not recruiting.
02
Drugs
Hepatitis B vaccineparoxetine
03
Conditions
hepatitis B (HBV)obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NL-OMON38586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38586.